The verdict follows a lawsuit brought by the biologist whose career collapsed after sexual misconduct allegations by a younger lab colleague.

The setback weighs on BNTX shares and raises questions about the company's oncology vaccine pipeline.

Positive late-stage cancer vaccine data and index inclusion boosted Moderna and related mRNA names.

The rolling submission advances the optogenetic therapy toward potential approval for retinal disease.

The company reported weight-loss benefits in a diabetes trial for its newer obesity drug candidate.

The approval adds a new option for patients with advanced melanoma that has resisted prior treatment.

The label expansion extends Anktiva's use in non-muscle invasive bladder cancer, a focus for ImmunityBio.

India's pricing authority moved to reduce trade margins on oncology medicines.

The Indian regulator cleared Lupin's biosimilar version of the checkpoint inhibitor nivolumab.

A systematic review examines in vivo CAR-T approaches aimed at making living drugs scalable.

Base editing faces a regulatory reckoning a decade after its promise emerged.

The acquisition marks Mankind's move into next-generation cancer therapies.

A major study questions earlier findings linking mRNA vaccines to improved cancer immunotherapy outcomes.

The Cambridge biotech raised fresh capital to push its microbiome-based therapy into mid-stage trials.

Early-stage data showed improved motor ON-time for the Parkinson's cell therapy.

Wall Street dismissed the sell-off following the gene therapy approval.

Retail sentiment peaked before the company's first late-stage trial data for its gene-editing therapy.

Researchers reported a viral protein approach to strengthen self-amplifying mRNA vaccine responses.